Objectives. To identify predictors of organ damage and specifically the relationship between prolonged disease remission or low disease activity and damage accrual in a longitudinal cohort of SLE patients.
Introduction
Mortality rate in SLE has dramatically decreased over the past five decades [1] . Despite improved survival, patients suffer from irreversible organ damage, which accumulates gradually during the disease course [2] . Organ damage, usually measured with the SLICC/ACR Damage Index (SDI) [3] , can accumulate due to SLE activity, its treatment [e.g. glucocorticoids (GCs) and CYC] and/or co-morbidities (e.g. cardiovascular disease and malignancy). Existing organ damage is predictive of further organ damage [4] . More importantly, higher SDI scores are associated with an increased mortality risk [5] . Therefore, identifying predictors of organ damage holds great importance for improving outcome in SLE. Previous cohort studies have demonstrated several factors to be associated with damage accrual, among which are male gender [6] , age at onset [7] , disease duration [8] , non-Caucasian ethnicity [9] , higher disease activity [10] , occurrence of flares [11] , lower income [12] , GC use [13] , CYC use [14] and hypertension [12] . In contrast, use of antimalarials has been negatively associated with damage accrual [15] .
Recently, a task force of SLE experts was formed to investigate whether a treat-to-target approach in SLE is feasible to improve outcome [16] . From their search of the literature it became apparent that internationally accepted criteria for disease remission are highly needed [17] . However, there is still much debate as to how to define remission [18] . Currently, several definitions of remission are in use. Zen et al. [19] formulated three remission definitions based on SLEDAI-2K, use of immunnosuppressants and prednisone dose. According to their definitions, disease remission during 5 years was associated with lower odds of damage accrual. Importantly, up to 37.5% of patients were able to achieve prolonged remitted disease in this study. Other studies, using more stringent definitions, showed lower percentages of prolonged remission [2022] .
Rather than finding consensus on remission, the Asia Pacific Lupus Collaboration (APLC) defined criteria for low disease activity termed Lupus Low Disease Activity State (LLDAS), using a Delphi approach [23] . From 191 patients with a mean follow-up of 3.9 years, 38.2% patients were 550% of time in LLDAS, which was associated with a lower risk of damage accrual (risk ratio (RR) = 0.47). Both Zen et al. and APLC assessed disease activity at every 34 monthly visit at their respective clinics.
In the present study, we aimed to identify predictors for damage accrual. Secondly, we assessed the relationship between both prolonged disease remission and low disease activity and damage accrual in a cohort of SLE patients who are prospectively investigated at a time interval of once a year.
Methods
Data from patients included in the Amsterdam SLE cohort were used for this study [24] . Inclusion criteria for this cohort are a diagnosis of SLE according to the updated revised ACR criteria for SLE [25] , and age 18 years or older upon inclusion. A study physician assesses all patients once a year and collects relevant data. Patients with at least 1 year follow-up were selected for this study. Written informed consent was obtained from all patients according to the Declaration of Helsinki. The VU University medical center Medical Ethics Committee approved this study (study number: NL17200.029.07).
Variables
Demographic factors included age, sex and ethnicity. Disease-related factors assessed included age at diagnosis, disease duration and number of ACR criteria at diagnosis and during follow-up. Other variables collected at baseline included hypertension, baseline, BMI and income.
Organ damage was assessed once a year at the study visit using the SDI [3] . Damage accrual was defined as an increase in SDI from baseline of 51. We attributed damage accrual to be most likely due to GC use with respect to the following SDI items: cataract, osteoporosis with fracture or vertebral collapse, avascular necrosis and diabetes. Likewise, damage accrual was arbitrarily attributed to disease activity with respect to the following SDI items: transverse myelitis, any renal damage, pulmonary hypertension, shrinking lung, pericarditis for 6 months or pericardectomy, chronic peritonitis, chronic pancreatitis, deforming or erosive arthritis, osteomyelitis and any skin damage. All other SDI items were defined as other or combined causes.
Cumulative doses of GCs were calculated for each individual patient at every study follow-up visit, from which mean daily doses were calculated. Current and previous use of HCQ and use of immunosuppressants (defined as use of either AZA, MTX, MMF, CYC, ciclosporin A or rituximab) were assessed at every visit. Disease activity was measured once a year using SLEDAI-2K [26] . Mean SLEDAI-2K was calculated as the sum of disease activity scores divided by the number of measurements.
Assessment of flares
At each cohort visit, flares that occurred since the previous visit were assessed by chart review. Patients included in our cohort are assessed 34 times a year on average by their treating rheumatologist in our centre. All changes in immunopsuppressive medication are made by or discussed with the treating rheumatologist and documented. Therefore, any flare that occurred during the follow-up period, also in between study visits, was documented and available for analysis. Flare definitions as proposed by Bootsma et al. [27] were used, in which flares are defined as an increase in disease activity or the occurrence or specific disease manifestations, both with the need for intensification of immunosuppressive therapy. In addition, flares according to the criteria used by Bootsma et al. are further subclassified into minor and major flares, depending on flare severity. Major flares include, among others, severe LN (proliferative with >50% affected glomeruli), or severe CNS disease (such as seizures and psychosis). Minor flares are defined as an increase in SLEDAI 52 points within a 6-month period with a minimal total SLEDAI score of 4, accompanied by the need to start GCs or immunosuppressive drugs based on clinical evidence [27] .
Assessment of remission
Criteria for remission as previously described by Zen et al. [19] were applied. Zen et al. define three types of remission: complete remission, that is, SLEDAI-2K = 0-antimalarials are the only immunosuppressants allowed; clinical remission off GCs, that is, maximum SLEDAI-2K of 4, with only hypocomplementaemia and presence of anti-dsDNA allowed-antimalarials and immunosuppressants are allowed, but no GCs; and clinical remission on GCs, that is, maximum SLEDAI-2K of 4, with only hypocomplementaemia and presence of anti-dsDNA allowed-antimalarials, immunosuppressants and equivalent doses of prednisone up to 5 mg daily are allowed. In our analysis, we categorized patients as being in remission, that is, fulfilling any of the three definitions of remission, or not in remission, that is, not fulfilling any of the three definitions of remission, unless explicitly specified otherwise. Prolonged remission was defined as being in remission at five consecutive cohort years.
LLDAS
Criteria for LLDAS were applied as published [23] . Presence of LLDAS depends on five criteria: SLEDAI-2K 44 with no activity in major organ systems (renal, CNS, cardiopulmonary, vasculitis, haemolytic anaemia, fever) or gastrointestinal activity; no new feature of lupus disease activity compared with the previous assessment; Safety of Estrogens in Lupus Erythematosus-National Assessment (SELENA)-SLEDAI physician global assessment (PGA) (03) 41; current prednisolone (or equivalent) dose 47.5 mg daily; and well tolerated standard maintenance doses of immunosuppressive drugs or approved biologic agents. All individual LLDAS criteria were assessed similar to the original criteria with the exception of PGA. PGA in our cohort was assessed using a 010 Likert scale, instead of the SELENA-SLEDAI PGA (03). We converted our PGA score into the SELENA-SLEDAI PGA by defining our PGA 42 on a 010 Likert scale into a SELENA-SLEDAI PGA of 41 on a 03 scale.
Missing data
When patients missed a cohort visit, we determined medication used (including cumulative GC dosages) and flares that occurred between visits, as these variables were reliably retrievable from chart review. SLEDAI-2K, PGA, SDI, LLDAS and remission status were not retrospectively assessed and were treated as missing data.
Statistical analysis
Descriptive statistics were used to compare selected variables in patients with at least 1 year follow-up based on damage accrual (yes/no), prolonged remission during 5 years (yes/no) or LLDAS in 550% of observations (yes/no). The chi-square test was used for categorical data, Student's t test for normally distributed data, and the MannWhitney U test for non-normally distributed data. To determine which variables were predictive of damage accrual (dependent variable), variables with P < 0.10 in univariate analysis were entered into the respective multivariate logistic regression model in a backward stepwise elimination manner. The strength of the final model was tested with receiver operating characteristics expressed as an area under the curve with a 95% CI and HosmerLemeshow goodness-of-fit test. Secondly, single logistic regression models were constructed to associate achievement of prolonged remission in patients with 5 years of follow-up (independent variable), or LLDAS in 550% of observations in patients with 51 years of follow-up (independent variable) with damage accrual (dependent variable). P < 0.05 was considered statistically significant. All data were analysed using SPSS Statistics version 20.0 (IBM Corp., Armonk, NY, USA).
Results
At the time of analyses, 192/224 patients in the Amsterdam SLE cohort had at least 1 year of follow-up. Nine patients were excluded due to missing essential data. As such, 183 patients were included in this study. In total, 858 yearly visits were analysed, representing a mean 4.7 yearly visits per patient. During follow-up, 54 patients missed 69 visits. The majority of patients were female and of Caucasian ethnicity. Mean disease duration at cohort inclusion was 8.1 years, with a median follow-up duration of 5.0 years (Table 1) . Anti-dsDNA titres were positive in 60.1% of patients at baseline. [19, 25] .
Thirty-four patients were lost to follow-up. Reasons for loss to follow-up were death (n = 10), declined further follow-up (n = 9), emigration or relocation (n = 3), other (n = 12). Mean age at death was 63.4 years (range 5075 years), median disease duration was 17 years (range 739 years). Median SDI at the time of death was 6 (range 012). Cause of death was infection in three patients, malignancy in two, cardiovascular disease or event in two and other causes in three.
At baseline, 100/183 patients (54.6%) had an SDI of 51. At baseline, renal damage was the most frequently observed type of organ damage (19.1%), followed by musculoskeletal (14.2%), neuropsychiatric (11.5%) and cardiovascular (11.5%) damage. During follow-up, damage occurred in all organ systems except for gonadal failure. Damage accrual steadily progressed during followup (Fig. 1) .
Predictors of damage accrual Table 1 shows the results of univariable analyses of variables between patients with and without accrual of organ damage during follow-up. Patients with damage accrual had higher median SDI scores, higher mean number of fulfilled ACR criteria, a higher frequency of nephrological manifestations and more frequently hypertension at baseline, higher mean SLEDAI-2K, higher mean daily doses of prednisone and a higher frequency of 51 major flare during follow-up, and lower frequency of remission at all visits and 550% of observations in LLDAS compared with patients without damage accrual.
Major flares occurred in 27 out of 183 patients, of whom nine patients had two major flares and one patient experienced three major flares. Mean flare rate (including both major and minor flares) during follow-up was 0.21 per patient per year. Two out of eight deceased patients www.rheumatology.oxfordjournals.org experienced a minor flare during follow-up, but not in the year preceding death and none had a major flare.
During follow-up 58.5% used oral prednisone at any visit. Patients with damage accrual used prednisone more frequently than patients without damage accrual (72.9 vs 51.6%, respectively, P = 0.007). Patients with a mean daily oral prednisone dose of >7.5 mg and >5 mg, respectively, had a higher risk of damage accrual (odds ratio (OR) = 3.6, 95% CI: 1.8, 7.2, and OR = 2.8, 95% CI: 1.5, 5.3, respectively) compared with those with lower doses.
A prediction model was constructed with variables identified from univariable analyses. The final prediction model comprised major flares, mean daily oral prednisone dose during follow-up, and nephrological manifestations up until baseline ( Table 2 ). The area under the curve of the Remission at all visits according to any of the three definitions of remission [19] . b Disease manifestations according to the 1997 ACR classification criteria for SLE [25] . SDI: SLICC damage index; LLDAS: Lupus Low Disease Activity State. prediction model was 0.70 (95% CI: 0.61, 0.78) and the HosmerLemeshow goodness-of-fit test was non-significant (P = 0.366). Post hoc analysis revealed no interaction between major flares and mean daily oral prednisone dose (P = 0.90).
Remission according to the criteria of Zen et al.
Prolonged remission as defined by the criteria according to Zen et al. [19] was assessed in patients with 5 years of follow-up. Table 3 shows the frequency of remission, both incidental and cumulative and categorized by the three levels of remission, throughout follow-up. Percentages of incident remission remained stable during follow-up. Prolonged remission was present in 44/117 (37.6%) patients. Out of these 44 patients, 7 patients were in complete remission at all visits, 31 patients were in clinical remission off GCs or complete remission at all visits and 9 patients were in clinical remission on/off GCs or complete remission at all visits. Table 4 shows that patients in prolonged remission had lower SLEDAI-2K, fewer ACR criteria, lower frequency of nephrological manifestations before study entry and lower median prednisone dose (all at baseline), suggesting that patients with a more severe disease at baseline are less likely to achieve prolonged remission during follow-up. None of the deceased patients were in the group with prolonged remission as none of them completed 5 years of follow-up. Prolonged remission was associated with reduced damage accrual (Table 3 ) (OR = 0.20, 95% CI: 0.07, 0.53, P = 0.001). Patients in prolonged remission (n = 44) together accrued 12 points of damage during follow-up of which one was attributed to disease activity, seven to GC use and four to other or combined causes. Patients not in remission (n = 73) together accrued 58 points of damage during follow-up of which 17 were attributed to disease activity, 9 to GC use and 32 to other or combined causes.
LLDAS
Frequencies of LLDAS are presented in Table 3 . Seventysix per cent (139/183) of patients were in LLDAS at least once and 64.5% (118/183) of patients were in LLDAS in at least 50% of observations. Differences between patients achieving LLDAS in 550% observations or not are presented in Table 4 . Patients with LLDAS in 550% of observations were more frequently Caucasian, older at study entry and at diagnosis, had a lower SLEDAI-2K, and used fewer immunosuppressants and less prednisone at study entry. Six out of eight deceased patients were in LLDAS in According to the 1997 ACR classification criteria for SLE [25] .
www.rheumatology.oxfordjournals.org 550% of observations. Patients with 550% of observations in LLDAS had a lower odds of damage accrual (OR = 0.52, 95% CI: 0.28, 0.99, P = 0.046). Patients with 550% of observations in LLDAS together accrued 45 damage points in total (10 attributed to disease activity, 13 to GC use, 22 to other or combined causes) compared with 47 damage points in total (14 attributed to disease activity, 11 to GC use, 22 to other or combined causes) in patients with <50% of observation in LLDAS.
A subanalysis between presence of LLDAS 550% of observations and damage accrual was performed for 117 patients with 5 years follow-up, which demonstrated a similar OR of damage accrual (OR = 0.50, 95% CI: 0.23, 1.10, P = 0.081).
A history of nephrological manifestations at baseline is not part of the criteria for remission or LLDAS, but was an important predictor for damage accrual in our study. After correcting for a history of nephrological manifestations at baseline, the association between prolonged remission and damage accrual remained statistically significant (adjusted OR = 0.25, 95% CI: 0.09, 0.67, P = 0.006), whereas the association between LLDAS and damage accrual was borderline statistically non-significant (adjusted OR = 0.53, 95% CI: 0.28, 1.02, P = 0.056).
Discussion
In the present study, we present for the first time longitudinal data regarding disease activity and damage accrual in our cohort. We found the occurrence of at least one major flare and mean daily prednisone dose during follow-up, as well as nephrological manifestations at baseline to be the most significant predictors of damage accrual. Most interestingly, this study shows for the first time in a single cohort that fulfilling definitions for prolonged disease remission or LLDAS (which included GC use as a criterion) are both associated with a lower risk of damage accrual in patients with SLE from one cohort. Importantly, whereas in previous studies LLDAS and remission were assessed at every 34 monthly visit at the outpatient clinic [19, 23] , we assessed LLDAS and remission once a year. While assessment of disease activity (including serological activity) at each outpatient visit provides detailed information on disease status during the follow-up period, the time needed and costs of laboratory assessments may not be feasible in routine clinical practice. Our study demonstrates similar risk of damage accrual for patients in remission or LLDAS with yearly assessments compared with previous studies by Zen et al. and APLC [19, 23] . This finding is interesting because it suggests that in clinical practice, yearly-rather than quarterly-assessments of LLDAS and remission might be sufficient to identify patients at risk of damage accrual, although future studies are needed to confirm this finding.
Variables associated with damage accrual in univariable analyses are similar to those reported from other cohort studies: baseline SDI, disease flares, number of ACR criteria at baseline, history of nephrological manifestations, GC use and hypertension [28] . Occurance of major flares was a strong predictor of damage accrual in our study. Prevention of flares however, is currently difficult to target, as biomarkers with sufficient sensitivity and specificity to predict flares on a patient level are lacking. Therefore, new biomarkers for the prediction of SLE flares are urgently needed. Prolonged remission and LLDAS are both also interesting targets from a treat-to-target perspective. Neither set of criteria showed clear superiority over the other, although patients in prolonged remission did seem to accrue less damage compared with patients in LLDAS for 550% of observations as was illustrated, but not proven, in our study. Future studies with sufficient power are needed in order to directly compare both sets of criteria for superiority.
Regarding prolonged remission, Zen et al. showed a similar reduced risk of damage accrual in patients who achieved prolonged remission (OR = 0.34 Zen et al. vs OR = 0.20 in our study, P < 0.05 for both). SDI scores at baseline were comparable between both studies, but a higher percentage of patients developed damage accrual during follow-up in the study by Zen et al. (41.9% vs 32.2%), which could be explained by the exclusion of patients who were already in remission for 12 months at study entry in the study of Zen et al. Prolonged remission was observed in approximately a third of patients (32.2%) in our study and the study by Zen et al (37.5%), suggesting that targeting remission according to these definitions is an achievable goal. Similarly, low disease activity defined as LLDAS was also demonstrated to be an achievable goal in the study by Franklyn et al. and our study (88.5 and 76.0% of patients, respectively, had at least one period of LLDAS). International consensus on remission criteria is, however, lacking, which is why an international panel of experts is currently aiming to define these criteria [29] . Our study is limited by a relative small sample size. As a consequence, we were unable to perform subanalyses on damage accrual in incident SLE cases or compare damage accrual between patients who are serologically active but clinically quiescent vs other forms of remission. Secondly, as we assessed remission and LLDAS once a year and not at every clinic visit, we could not directly compare within our cohort whether once a year assessments yield similar risks on damage accrual as assessments at each visit. Thirdly, our cohort mainly consists of patients of Caucasian ethnicity, which did not allow us to further investigate differences in remission and LLDAS between subgroups of SLE patients from different ethnic backgrounds such as Asians and Africans. Finally, although the flare criteria applied in our study are used infrequently, they are rather similar to the more frequently used SELENA-SLEDAI flare definitions, which also define an increase in disease activity in combination with the need to intensify immunosuppressive treatment as criteria for (minor or major) flares.
In conclusion, we confirm that fulfilling criteria for remission during 5 years as well as reaching LLDAS in 550% of observations were both associated with reduced damage accrual in SLE. Future studies should address which criteria are superior in predicting reduced damage accrual. Furthermore, intervention studies aiming at prolonged remission or low disease activity as the primary outcome parameter are advocated in order to investigate whether actively achieving prolonged remission or LLDAS is feasible and whether this approach will lead to reduced organ damage, an increased quality of life and an improved survival of SLE patients.
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